Consecutive patients undergoing circumferential PV isolation at our centre between April 2008 and April 2010 were included in this study. All patients had conventional indications with symptomatic AF and a failed attempt to maintain sinus rhythm with antiarrhythmic medication [¹]. Conventional manual AF ablation was introduced at our center in 2006. The RMN-system was utilized for all AF ablation procedures beginning November 2008. The control group consisted of those 54 consecutive patients that underwent conventional manual ablation (CON) between April and October 2008 (before switching to RMN-guided ablation).

Exclusion criteria were hyperthyroidism, LA thrombus, decompensated heart failure, stroke, myocardial infarction or gastrointestinal bleeding within 4 weeks prior to the intervention, and life-expectancy <6 months.

In all subjects, left atrial (LA) thrombi were excluded by transesophageal echocardiography, and LA anatomy was acquired by high-resolution thoracic computer tomography imaging just prior to the procedure. All ablation procedures were performed during conscious sedation using intravenous sufentanil, midazolam and/or propofol under continuous monitoring of blood pressure and oxygen saturation.

For the electrophysiological procedure, all catheters were advanced via the femoral vein. A 6F steerable decapolar catheter (Bard Dynamic Tip, Bard Inc., Lowell, MA, USA) was positioned in the coronary sinus. After a fluoroscopically guided transseptal puncture an SL1 sheath (St. Jude Medical, Inc., St. Paul, MN, USA) in the RMN group or an Agilis deflectable sheath (St Jude Medical) in the CON group were advanced into the LA. Intravenous heparin was administered immediately after the transseptal puncture to maintain an activated clotting time of 250–300 s throughout the procedure. In the RMN group, a 3.5 mm open-irrigated, magnetic mapping and ablation catheter (Navistar Thermocool RMT, Biosense Webster, Diamond Bar, USA) was advanced through the sheath into the LA, whereas in the CON group a manually guided 3.5 mm open-irrigated mapping and ablation catheter (Navistar Thermocool, Biosense Webster) was used. Patients presenting with sustained atrial fibrillation underwent electrical cardioversion for mapping and ablation.

Circumferential pulmonary vein ablation was performed using a three-dimensional mapping system (CartoMerge XP, Biosense Webster) in conjunction with the integrated CT image of the LA and real-time fluoroscopy. In the RMN group, the Niobe II magnetic navigation system (Stereotaxis) and a joystick-controlled motor drive (Cardiodrive, Stereotaxis) were utilized for remote magnetic navigation of the ablation catheter, whereas in the CON group the ablation catheter was guided manually.

The RMN system has been described in detail elsewhere [¹⁰]. Briefly, two permanent magnets located on either side of the procedure desk generate a magnetic field (0.08 Tesla) within the patient. The magnetic ablation catheter incorporates four magnets in the distal portion of the catheter. A change of the desired vector for catheter orientation on a computer screen results in alteration of the magnetic field generated by the permanent magnets and thereby corresponding deflection of the magnetic catheter within the heart. The joystick-controlled motor drive allows catheter advancement and retraction. Thus, the system provides complete remote catheter navigation for mapping and ablation.

The radiofrequency (RF) generator (Stockert, Biosense Webster) was set to temperature controlled RF delivery with a target temperature of 45°C and a nominal power limit of 40 W (flow 30 ml/min) and 30 W (flow 17 ml/min) at the posterior LA wall. RF current was applied for 30–60 s until local electrogram amplitude was reduced by 80%. Endpoint of the ablation procedure was the electrical isolation of all PVs defined as bidirectional conduction block. This was verified by careful and repeated mapping for residual potentials around the entire circumference of the PV ostia, and pacing from multiple sites within the circumferential line.

All patients were monitored in the hospital at least overnight. Echocardiography was performed within 24 h after the procedure and in cases of unexplained hypotension to rule out pericardial effusion. On the day after the procedure, the venous puncture site was inspected for significant local hemorrhage, and a 12-lead surface ECG was acquired to confirm normal sinus rhythm. Antiarrhythmic medication was administered according to the investigators discretion. Oral anticoagulation was restarted the day after the procedure with a target INR of 2.0–3.0. Bridging with unfractionated or low molecular weight heparin was initiated 6–12 h after the procedure. After hospital discharge, all patients were followed in our outpatient clinic every 3 months for at least 1 year. At each visit, subjects were asked for symptoms, documented arrhythmia recurrences, and current medication was assessed. Ambulatory holter monitoring was performed for 7 days at each follow-up to reveal possible arrhythmia recurrences. Furthermore, all patients were advised to present immediately in case of symptoms suggestive for arrhythmia recurrence and obtain ECG documentation. A documented AF or left atrial tachycardia (AT) episode lasting longer than 30 s outside a blanking period of 2 months after the index procedure were considered as recurrent AT/AF. Additional diagnostic information (e.g., echocardiogram, chest X-ray/computertomography) was acquired if symptoms were suggestive of procedure-related complications (e.g., pericardial effusion, pulmonary vein stenosis).

The primary endpoint of this prospective observational study was acute procedural success, defined as the number of PVs isolated at the end of the procedure. Secondary endpoints were long-term procedural success, defined as long-term freedom from any AT/AF episodes irrespective of symptoms after the index procedure during 12 months of follow-up, and survival without symptomatic AF recurrence after the index procedure during 12 months of follow-up. Further secondary endpoints were freedom from symptomatic AF recurrence at the end of the individual observation period after the last PV ablation procedure irrespective of the number of PV ablations combined for both groups, procedure duration, ablation duration (defined as time from the first to the last ablation point), RF current application duration, fluoroscopy time, and procedure-related complications. Procedure-related complications were defined as death, atrio-esophageal fistulae, pulmonary vein stenosis requiring interventions, pericardial tamponade requiring drainage, systemic embolic events, phrenic nerve paralysis, femoral vessel damage requiring surgery, blood transfusion or prolongation of hospitalisation, and clinically and radiologically verified infections.

Continuous variables are expressed as mean ± standard deviation or as median with inter-quartile range if appropriate. Normally distributed data were compared using the independent Student’s t test. Otherwise, comparisons between groups were performed using the Mann–Whitney U test. One-way ANOVA or Kruskal–Wallis ANOVA (with Dunns post hoc test) were used to test for learning curve effects. A Kaplan–Meier analysis with the log-rank test was used to determine the probability of freedom from recurrent AT/AF. All tests are two-tailed. A p value < 0.05 is considered statistically significant.

We expected a mean acute PV isolation rate of 3.5 ± 0.6 PVs per patient. Based on this assumption a sample size of 100 RMN and 50 control patients would allow detection of a difference in acute PV isolation of 0.3 PVs with 80% power and a two-tailed alpha of 5%.

A total of 161 patients were included. Data from 107 patients in the RMN group and 54 patients in the CON group were analysed. Patient baseline characteristics are illustrated in Table 1 and were comparable between groups. In both groups, about two-thirds of the patients were in persistent AF, defined as AF lasting >7 days or requiring cardioversion according to current guidelines [¹¹]. The persistent AF cohort included three patients with long-standing persistent AF (lasting for ≥1 year) in the CON group and two in the RMN group. In both groups, 22% of the patients had a prior circumferential pulmonary vein ablation before the index procedure.

At the end of the index procedure 3.7 ± 0.8 PVs in the CON group and 3.8 ± 0.7 PVs in the RMN group were isolated (p = 0.34). Electrical isolation of all PVs was achieved in 90% of the RMN-guided cases and in 87% of the subjects in the CON group (p = 0.6).

By Kaplan–Meier analysis, the percentage of patients who were free of any AT/AF episode at 12 months of follow-up was 53.5% in the RMN group and 55.5% in the CON group (p = 0.57, Fig. 1). As illustrated in Fig. 2, the percentage of patients who were free of symptomatic AF recurrence at 12 months of follow-up was 66.3% in the RMN group and 62.1% in the CON group (p = 0.80). Antiarrhythmic drugs were prescribed to 25% of the patients without symptomatic AF recurrence in the CON group (n = 32) and to 29% in the RMN group (n = 36). Of those patients, 10% in the CON group and 11% in the RMN group were on amiodarone.

In both the RMN and CON group, long-term success rates (as defined by freedom from AT/AF during follow-up) tended to be higher in patients with a history of paroxysmal versus persistent AF (RMN: 66 vs. 49%; CON: 63 vs. 52%) and in patients with LA diameter ≤45 mm as compared to LA > 45 mm (RMN: 67 vs. 44%; CON: 64 vs. 47%) (Fig. 3).

Freedom from symptomatic AF combining both groups after a follow-up duration of 382 ± 187 days and 1.5 ± 0.6 PV isolations (including PV isolations before the index procedure) was 83%. Following the index procedure, additional PV ablation procedures were considered only outside the blanking period and were performed in 23% of the patients in the RMN group and in 24% of the patients in the CON group. A total of 40% of these patients were on antiarrhythmic drugs at the end of the respective observation period with 14% of the patients being on amiodarone.

As illustrated in Fig. 4, use of the RMN system was associated with longer procedure duration (RMN: 225.5 ± 54.6 min, CON: 165.6 ± 52.4 min, p < 0.0001), longer ablation times (RMN: 125.3 ± 46.5 min, CON: 79.6 ± 28.5 min, p < 0.0001) and longer RF current application duration (RMN: 50.4 ± 17.7 min, CON: 43.9 ± 11.0 min, p < 0.05) as compared to the CON group. In contrast, fluoroscopy time was lower in the RMN [12 (9–17) min] than in the CON [37 (29–44) min] group (p < 0.0001). Furthermore, fluoroscopy time significantly decreased in the RMN group over time (Fig. 5). No learning curve effect was observed for the remaining procedural parameters (procedure duration, ablation time and RF current application duration).

Major complications occurred in 6 of the 161 procedures (3.7%), with no significant difference between the 2 treatment groups (p = 0.75). One procedure-related complication was observed in the CON group (aspiration pneumonia). In the RMN group, procedure-related complications were cardiac tamponade requiring pericardial puncture (n = 2), hematoma after femoral vein puncture requiring blood transfusion (n = 1) or prolonging hospital stay (n = 1), and transient ischemic attack (n = 1). Cardiac tamponades occurred subacutely, in one case 30 min after the end of an uneventful procedure, in the other subject several hours after an uncomplicated ablation.

The main finding of this prospective observational study is that RMN-guided circumferential PV ablation with an open-irrigated mapping and ablation catheter results in comparable acute and long-term success and complication rates as compared to the CON approach. Utilization of the RMN system reduces fluoroscopy time, but increases ablation and total procedure times as compared to the CON ablation technique.

Manually guided RF ablation for PV isolation has emerged as a standard second line treatment in patients with symptomatic AF [¹]. Nevertheless, efforts continue to improve success rates and patient safety as well as procedural efficacy reducing procedure times and radiation exposure to patients and operators.

In our analysis, acute isolation of all PVs and long-term freedom from symptomatic AF or any AF/AT was achieved in a comparable proportion of patients in the RMN and the CON group. So far, only limited data are available on the clinical utility of the RMN system for catheter-based PV isolation [⁵–¹⁰]. Early reports used non-irrigated ablation catheters, which limits the comparability to our results [⁷, ⁸, ¹⁰]. Very recently, first reports on the efficacy of RMN-guided PV isolation with an open-irrigated ablation catheter have been published by single centers [⁵, ⁶, ⁹]. Chun et al. [⁶] evaluated the efficacy of an RMN-guided open-irrigated ablation catheter in a pre-market design and compared it to the efficacy of the advanced, marked-released RMN catheter. With the currently available catheter, the group achieved isolation of all PVs in 93% of the cases, and 70% of the patients remained in sinus rhythm during a median follow-up of 18 months. Arya et al. [⁵] report in their retrospective analysis complete isolation of all PVs during RMN-guided PV ablation with an open-irrigated catheter in 88% of the cases. Sixty-one percent of the RMN patients as compared to 68% in the conventional group remained free from AF after 6 months of follow-up. The retrospective analysis by Miyazaki et al. [⁹] demonstrated acute isolation of all 4 PVs in 87% of the 30 patients investigated with an RMN-guided open-irrigated catheter. At 12 months of follow-up after a single procedure, 69% of the patients were free of AF recurrence without antiarrhythmic drugs as compared to 62% in the manual group.

In the present study, long-term freedom from symptomatic AF was achieved in 83% of all patients with 1.5 ± 0.6 PV isolations. This data is in line with the general success rate from a recent meta-analysis from Cappato et al. [³], who reported that 85% of the patients were free from symptomatic AF after a median of 1.4 procedures. The long-term freedom from any AT/AF after a single procedure observed in our study is comparable to recently published data by Wilber et al. [¹²]. However, a meta-analysis by Calkins et al. [¹³] revealed a single procedure success rate of 72% (on or off antiarrhythmic medication). The lower procedure success rate in our study as compared to this meta-analysis and the study by Chun et al [⁶] and Miyazaki et al. [⁹] may have several explanations. First, a larger proportion of patients in our study had enlarged left atria or presented with persistent AF. Several prior investigations as well as our own data indicate that these factors may influence the success of AF ablation [³, ¹⁴–¹⁶]. Second, we performed PV isolation without additional ablation also in patients suffering from persistent AF. In these subjects, PV isolation combined with linear lesions (e.g., mitral isthmus line) and/or ablation of complex fractionated electrograms may increase the success rate of the procedure [¹⁷]. This may potentially occur at the cost of an increased incidence of atrial tachycardias [¹⁸, ¹⁹] and other procedural complications [², ²⁰]. At our institution, we therefore prefer an approach to combine the effects of circumferential PV isolation with antiarrhythmic medication as needed. This concept can explain the higher proportion of patients on antiarrhythmic drugs in our study but is supported by the relatively low incidence of major complications. Third, we verified electrical isolation of the PVs without the aid of a circular mapping catheter. Although the use of a circular mapping catheter is still considered as the gold standard to ensure complete PV isolation, growing evidence exists [²¹–²³] that a single-catheter approach (as utilized also in our study) may be equally effective for the achievement and verification of PV isolation [²¹, ²²] and for the prevention of AF recurrences during follow-up [²³]. We decided to apply the single-catheter approach for mapping and ablation since the use of a manually guided circular mapping catheter increases the complexity of the procedure and contradicts the concept of remote navigation.

The use of RMN in the present investigation was associated with considerably shorter fluoroscopy times as compared to the CON approach, despite longer ablation times. In the RMN group fluoroscopy time decreased significantly over the course of the study. This benefit of RMN-guided ablation has previously also been observed by our group [²⁴] and other investigators [⁶, ⁸, ²⁵] in studies on different arrhythmias including AF. The reduction in fluoroscopy time associated with RMN-guided ablation may be explained by the fact that the risk of cardiac perforation is rather low with the flexible tip of the magnetic catheter tip as compared to the stiff tip of a conventional ablation catheter tip. Large catheter movements without frequent fluoroscopic visualization of the catheter tip can therefore be made safely only with the flexible tip of the RMN ablation catheter. In this context, it appears noteworthy that two cardiac tamponades occurred in the RMN group of our study. The sub-acute time course of these complications lets one speculate that repetitive ablation at the perforation site rather than mechanical perforation of the LA wall accounts for these complications. The RMN system may increase catheter stability and thereby local lesion size [²⁵–²⁷]. We therefore rigorously avoided prolonged RMN-guided RF current delivery at single locations after the cases of sub-acute pericardial effusion.

Our data indicate that more RF current has to be delivered when utilizing RMN-guided ablation as compared to the manual approach to achieve equally effective ablation lesions. This finding is in line with prior reports that suggest that RMN-guided ablation may produce less effective linear lesions [⁷, ²⁴] but may be at least equally effective for focal ablation targets [²⁵, ²⁶]. The maximal endocardial force exerted by the RMN-system to the magnetic catheter tip is generally lower than that applied manually to the conventional ablation catheter tip [²⁸]. Given the complex anatomy of the LA, one might assume that the tip-to-tissue contact may be insufficient to produce effective ablation lesions with the RMN system in locations that are difficult to reach (e. g., right inferior PV) and/or at regions with thicker myocardium (e.g., the ridge between left atrial appendage and left superior PV). In return, exactly this feature of RMN may be desirable for increasing safety of the procedure. In this study, the magnetic field strength used was 0.08 Tesla. Since recently, the magnetic navigation system can apply higher field strengths of 0.1 Telsa, which might enhance the effectiveness of the produced lesions.

Longer ablation times with RMN-guided ablation also translated into longer procedure times as compared to the CON group of our study. These are not necessarily explained by the longer RF application time, which amounted to 7 min on average. In addition, the preparation time before the start of mapping contributes in a minor fashion as we demonstrated earlier for RMN-guided ablation of typical atrial flutter [²⁴]. Rather an inherently slower speed in navigation of the LA or other cardiac chambers with RMN guided navigation as compared to manual navigation is reflected. When considering the numerous changes of catheter position necessary during the procedure, small delays between the computerized demand of vector direction change, movement of the permanent magnets and the magnetic field, and actual catheter movement must add to longer procedure times with RMN-guided circumferential PV isolation.

The main limitation is the non-randomized design of our study. Furthermore, inherent to AF studies asymptomatic episodes of AF may have been missed.

AAD antiarrhythmic drugs, AF atrial fibrillation, LA left atrium, LVEF left ventricular ejection fraction